This whitepaper outlines a practical framework for designing scientifically justified, regulatory-ready IND packages that ...

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

The field of drug discovery is undergoing a profound transformation. Traditional small-molecule and biologic therapeutics — long the backbone of modern medicine — are now joined by a new generation of ...

Discover how researchers are looking beyond individual neurons to understand how genetic variations shape activity across ...

Explore how dual binding assays reveal interactions between bispecific antibodies and their targets, providing insights into ...

The first proof-of-concept study showed that the gene therapy reduced the production of cerebrospinal fluid in the brains of ...

Explore how direct cell lysis can reduce sample preparation steps and support efficient gene expression analysis by RT-qPCR.

BCG vaccination reduced tau pathology and neuroinflammation in mice, prompting researchers to investigate whether trained immunity could inform future treatments for Alzheimer’s disease.

Antibody-drug conjugates are deceptively simple in concept: an antibody selectively delivers a cytotoxic payload to cancer cells. Manufacturing them at scale is anything but simple. ADC production ...

Advances in biolayer interferometry enable the analysis of small molecule interactions, providing new insights into binding kinetics and affinity.

On the one hand, lab technology has seen tremendous advancements in the past 50 years. The instruments are more sophisticated than ever and are powered by informatics solutions that enable scientists ...

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news. Vertex Pharmaceuticals announced this week that the FDA has accepted its Biologics License ...